AYTU — Stock Film
STOCK FILMSCENE 1/11AYTU · $2.19
Stock Expert AI presents
AYTU
Aytu BioPharma, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Aytu BioPharma, Inc. A quick introduction.

On the stock market since 2008, it operates in the world of health and science. It has 102 employees. Now — the numbers.

on the stock market since 2008
102 employees
$17.7M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.2.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are moving sideways.

No real growth. Red columns mark years that ended in a loss.

$65.6M
2021
$96.7M
2022
$107.4M
2023
$65.2M
2024
$66.4M
2025
In the vault right now:
$0
DEBT: $22.9M
At this pace, that money lasts about 2.3 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
43
weak

Clearly below the class average.

FINANCIAL STRENGTH
21
very weak

Clearly below the class average.

VALUATION
60
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
18
very weak

Clearly below the class average.

PRICE MOMENTUM
39
weak

Clearly below the class average.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
Few are betting against it10/10
WEAK SPOTS
Little set aside for the future2/10
Growth has stalled4/10
WORTH WATCHING

R&D Investment: Spending on future research is low.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Sales are holding up

The company sells $66.4M a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 16 buys and 4 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Running at a loss

A loss of $13.6M against $66.4M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 2.3 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, AYTU sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: AYTU is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film